Biotech & Health
The First RAS-Targeted Pancreatic Cancer Drug Just Changed the Math
RASONQUE (daraxonrasib) is the first approved drug to hit RAS directly, the driver behind 90% of pancreatic tumours. In RASolute 302 it doubled median survival. Then came the $39,800-a-month list price. We assess the clinical event against the commercial bet.
Defence & Robotics
Humanoid Robots Have a New Proof Metric: What 2026 Deployments Actually Show
Humanoids crossed from demo to deployment, but the evidence base is mostly vendor-authored. Agility's SPAC is about to price the gap for the first time.
Energy & Climate
Form Energy’s Down Round Masks a Fourfold Order Backlog
Form Energy raised $750M at a valuation roughly 40% below its last round while its iron-air order backlog quadrupled to 80 GWh. The down round is the market pricing industrial execution risk honestly.
AI & Infrastructure
AI Data Centre Capex: The $31.6 Trillion Build-Out That Never Ends
PwC's Global Data Centre Outlook models $31.6 trillion of AI infrastructure capex through 2050. The bulk buys hardware that refreshes every four to six years, so the build-out never ends. Power access and chip trade flows, not capital, decide which regions capture it.